Skyrizi® (Risankizumab-Rzaa) – Commercial Medical Benefit Drug Policyopen_in_new

Intravenous Skyrizi (risankizumab‑rzaa) is covered only as a three‑dose FDA‑labeled IV induction regimen for moderately to severely active Crohn’s disease or ulcerative colitis (authorization limited to the 3 induction doses), while self‑administered subcutaneous Skyrizi is generally obtained under the pharmacy benefit (except certain UnitedHealthcare of California delegated‑plan exceptions). Approval requires documentation of diagnosis and FDA dosing, that the patient is not receiving another targeted immunomodulator, and either prior failure/intolerance to specified conventional therapies or prior treatment with an FDA‑approved targeted immunomodulator, with therapy prescribed by or in consultation with a gastroenterologist.

"This policy refers to Skyrizi (risankizumab-rzaa) injection for intravenous use."

Sign up to see full coverage criteria, indications, and limitations.